Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

NCT04790409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: sintilimab and anlotinib

Sponsor

Zhejiang Cancer Hospital